Biogen BIIB
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
Key Insights
Biogen (BIIB) Core Market Data and Business Metrics
Latest Closing Price
$131.32Price-Earnings Ratio
11.86Total Outstanding Shares
146.38 Million SharesDividend
No dividendSIC Description
Biological Products, (no Disgnostic Substances)Primary Exchange
NASDAQHeadquarters
225 Binney Street, Cambridge, MA, 02142
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Short Interest
Track Short Interest Levels to Gauge Bearish Market Sentiment and Short Squeeze Potential
| Avg Daily Volume | Days to Cover | Settlement Date | Short Interest |
|---|---|---|---|
| 1,914,508 Shares | 1.73 | 3/14/2025 | 3,310,573 Shares |
| 1,620,071 Shares | 2.3 | 2/28/2025 | 3,719,971 Shares |
| 1,652,272 Shares | 2.35 | 2/14/2025 | 3,883,735 Shares |
| 1,286,729 Shares | 2.91 | 1/31/2025 | 3,741,109 Shares |
| 1,251,215 Shares | 3.01 | 1/15/2025 | 3,769,744 Shares |
| 1,668,315 Shares | 2.2 | 12/31/2024 | 3,676,606 Shares |
Cash Flow Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Exchange Gains/Losses | $54.60 Million |
| Net Cash Flow From Financing Activities | $-1.34 Billion |
| Net Cash Flow From Financing Activities, Continuing | $-1.34 Billion |
| Net Cash Flow From Operating Activities | $2.13 Billion |
| Net Cash Flow, Continuing | $-643.30 Million |
| Net Cash Flow From Operating Activities, Continuing | $2.13 Billion |
Income Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Gross Profit | $7.26 Billion |
| Basic Earnings Per Share | $11.11 |
| Costs And Expenses | $7.70 Billion |
| Income Tax Expense/Benefit | $291.70 Million |
| Diluted Average Shares | $146.10 Million |
| Diluted Earnings Per Share | $11.07 |
Comprehensive Income
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss | $1.63 Billion |
| Other Comprehensive Income/Loss | $13.60 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $-800,000 |
| Comprehensive Income/Loss Attributable To Parent | $1.63 Billion |
| Other Comprehensive Income/Loss Attributable To Parent | $13.60 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Other Non-current Liabilities | $1.98 Billion |
| Intangible Assets | $9.81 Billion |
| Accounts Payable | $422.70 Million |
| Inventory | $2.47 Billion |
| Other Non-current Assets | $8.47 Billion |
| Current Liabilities | $5.42 Billion |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||